Cargando…
Protein arginine methyltransferase 1 is a therapeutic vulnerability in multiple myeloma
Multiple myeloma (MM) is a devastating plasma cell malignancy characterized by the expansion of aberrant monoclonal plasma cells in the bone marrow, leading to severe clinical manifestations and poor prognosis, particularly in relapsed/refractory cases. Identifying novel therapeutic targets is cruci...
Autores principales: | Nguyen, Hong Phuong, Le, Anh Quynh, Liu, Enze, Cesarano, Annamaria, DiMeo, Francesco, Perna, Fabiana, Kapur, Reuben, Walker, Brian A., Tran, Ngoc Tung |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10436492/ https://www.ncbi.nlm.nih.gov/pubmed/37600810 http://dx.doi.org/10.3389/fimmu.2023.1239614 |
Ejemplares similares
-
Corrigendum: Protein arginine methyltransferase 1 is a therapeutic vulnerability in multiple myeloma
por: Nguyen, Hong Phuong, et al.
Publicado: (2023) -
Intron retention-induced neoantigen load correlates with unfavorable prognosis in multiple myeloma
por: Dong, Chuanpeng, et al.
Publicado: (2021) -
Protein Arginine Methyltransferase 5 (PRMT5) has prognostic relevance and is a druggable target in Multiple Myeloma
por: Gullà, Annamaria, et al.
Publicado: (2017) -
Protein arginine methyltransferase 6 is a novel substrate of protein arginine methyltransferase 1
por: Cao, Meng-Tong, et al.
Publicado: (2023) -
Protein arginine methyltransferase 3-induced metabolic reprogramming is a vulnerable target of pancreatic cancer
por: Hsu, Ming-Chuan, et al.
Publicado: (2019)